PenfluridolCAS# 26864-56-2 |
- Abacavir
Catalog No.:BCC1325
CAS No.:136470-78-5
- Adenosine
Catalog No.:BCN5796
CAS No.:58-61-7
- Cytidine
Catalog No.:BCN3415
CAS No.:65-46-3
- Orotic acid
Catalog No.:BCC4162
CAS No.:65-86-1
- Adenine
Catalog No.:BCC4450
CAS No.:73-24-5
- Leflunomide
Catalog No.:BCC1256
CAS No.:75706-12-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 26864-56-2 | SDF | Download SDF |
| PubChem ID | 33630 | Appearance | Powder |
| Formula | C28H27ClF5NO | M.Wt | 523.97 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | R-16341 | ||
| Solubility | DMSO : ≥ 100 mg/mL (190.85 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]piperidin-4-ol | ||
| SMILES | C1CN(CCC1(C2=CC(=C(C=C2)Cl)C(F)(F)F)O)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F | ||
| Standard InChIKey | MDLAAYDRRZXJIF-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C28H27ClF5NO/c29-26-12-7-21(18-25(26)28(32,33)34)27(36)13-16-35(17-14-27)15-1-2-24(19-3-8-22(30)9-4-19)20-5-10-23(31)11-6-20/h3-12,18,24,36H,1-2,13-17H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Penfluridol is a highly potent, first generation diphenylbutylpiperidine antipsychotic. |
Penfluridol Dilution Calculator
Penfluridol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9085 mL | 9.5425 mL | 19.0851 mL | 38.1701 mL | 47.7127 mL |
| 5 mM | 0.3817 mL | 1.9085 mL | 3.817 mL | 7.634 mL | 9.5425 mL |
| 10 mM | 0.1909 mL | 0.9543 mL | 1.9085 mL | 3.817 mL | 4.7713 mL |
| 50 mM | 0.0382 mL | 0.1909 mL | 0.3817 mL | 0.7634 mL | 0.9543 mL |
| 100 mM | 0.0191 mL | 0.0954 mL | 0.1909 mL | 0.3817 mL | 0.4771 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Penfluridol is a highly potent, first generation diphenylbutylpiperidine antipsychotic.
- Triptohypol F
Catalog No.:BCN5154
CAS No.:268541-26-0
- Homoharringtonine
Catalog No.:BCN4958
CAS No.:26833-87-4
- Harringtonine
Catalog No.:BCN6794
CAS No.:26833-85-2
- Coronalolic acid
Catalog No.:BCN5153
CAS No.:268214-52-4
- Coronalolide
Catalog No.:BCN5152
CAS No.:268214-51-3
- Coronalolide methyl ester
Catalog No.:BCN5151
CAS No.:268214-50-2
- Udenafil
Catalog No.:BCC5213
CAS No.:268203-93-6
- Debilon
Catalog No.:BCN7696
CAS No.:26808-51-5
- Indapamide
Catalog No.:BCC4788
CAS No.:26807-65-8
- Dehydrodiisoeugenol
Catalog No.:BCN1240
CAS No.:2680-81-1
- Xanthatin
Catalog No.:BCN5150
CAS No.:26791-73-1
- Robtein
Catalog No.:BCN4658
CAS No.:2679-65-4
- 1,3-Bis[2-(4-aminophenyl)-2-propyl]benzene
Catalog No.:BCC8419
CAS No.:2687-27-6
- Isomahanimbine
Catalog No.:BCN3175
CAS No.:26871-46-5
- 6-Hydroxybenzofuran-2(3H)-one
Catalog No.:BCN5155
CAS No.:2688-49-5
- Oxysophocarpine
Catalog No.:BCN5156
CAS No.:26904-64-3
- 2(-4-Chloro-3-hydroxy-1-butynyl)-5-1,(3-pentadiynyl)thiophene
Catalog No.:BCN1465
CAS No.:26905-70-4
- Etravirine (TMC125)
Catalog No.:BCC5027
CAS No.:269055-15-4
- Fmoc-Orn(Dde)-OH
Catalog No.:BCC3534
CAS No.:269062-80-8
- H-D-Dab-OH.2HCl
Catalog No.:BCC3185
CAS No.:26908-94-1
- Timolol Maleate
Catalog No.:BCC4340
CAS No.:26921-17-5
- Aglaxiflorin D
Catalog No.:BCN6594
CAS No.:269739-78-8
- 16-Acetoxy-7-O-acetylhorminone
Catalog No.:BCN5157
CAS No.:269742-39-4
- Sphingosine-1-phosphate
Catalog No.:BCC7034
CAS No.:26993-30-6
Anti-tumor effects of penfluridol through dysregulation of cholesterol homeostasis.[Pubmed:24528079]
Asian Pac J Cancer Prev. 2014;15(1):489-94.
BACKGROUND: Psychiatric patients appear to be at lower risk of cancer. Some antipsychotic drugs might have inhibitory effects on tumor growth, including Penfluridol, a strong agent. To test this, we conducted a study to determine whether Penfluridol exerts cytotoxic effects on tumor cells and, if so, to explore its anti-tumor mechanisms. METHODS: Growth inhibition of mouse cancer cell lines by Penfluridol was determined using the 3- (4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Cytotoxic activity was determined by clonogenic cell survival and trypan blue assays. Animal tumor models of these cancer cells were established and to evaluate Penfluridol for its anti-tumor efficacy in vivo. Unesterified cholesterol in cancer cells was examined by filipin staining. Serum total cholesterol and tumor total cholesterol were detected using the cholesterol oxidase/p- aminophenazone (CHOD-PAP) method. RESULTS: Penfluridol inhibited the proliferation of B16 melanoma (B16/ F10), LL/2 lung carcinoma (LL/2), CT26 colon carcinoma (CT26) and 4T1 breast cancer (4T1) cells in vitro. In vivo Penfluridol was particularly effective at inhibiting LL/2 lung tumor growth, and obviously prolonged the survival time of mice bearing LL/2 lung tumors implanted subcutaneously. Accumulated unesterified cholesterol was found in all of the cancer cells treated with Penfluridol, and this effect was most evident in LL/2, 4T1 and CT26 cells. No significant difference in serum cholesterol levels was found between the normal saline-treated mice and the Penfluridol-treated mice. However, a dose-dependent decrease of total cholesterol in tumor tissues was observed in Penfluridol-treated mice, which was most evident in B16/F10-, LL/2-, and 4T1-tumor-bearing mice. CONCLUSION: Our results suggested that Penfluridol is not only cytotoxic to cancer cells in vitro but can also inhibit tumor growth in vivo. Dysregulation of cholesterol homeostasis by Penfluridol may be involved in its anti-tumor mechanisms.
Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors.[Pubmed:27811009]
Mol Cancer Ther. 2017 Jan;16(1):205-216.
It was recently demonstrated the Penfluridol inhibited breast tumor growth and metastasis and this was associated with downregulation of alpha6- and beta4-integrins. In this study, we observed the Penfluridol induced reactive oxygen species (ROS) and this was the primary mechanism of action. Penfluridol-mediated growth inhibition, induction of apoptosis, and inhibition of breast cancer cell migration was attenuated after cotreatment with glutathione. Penfluridol also downregulated Sp transcription factors Sp1, Sp3, and Sp4 through epigenetic downregulation of cMyc and cMyc-regulated miRNAs (miR27a and miR20a/miR17) and induction of the miR-regulated Sp transcriptional repressors ZBTB10 and ZBTB4. alpha6- and beta4-integrins as well as alpha5- and beta1-integrins are Sp-regulated genes that are also coregulated by the orphan nuclear receptor NR4A1 and these integrins can be targeted by agents such as Penfluridol that suppress Sp1, Sp3, and Sp4 and also by NR4A1 antagonists. Mol Cancer Ther; 16(1); 205-16. (c)2016 AACR.
Penfluridol suppresses pancreatic tumor growth by autophagy-mediated apoptosis.[Pubmed:27189859]
Sci Rep. 2016 May 18;6:26165.
Pancreatic tumors exhibit enhanced autophagy as compared to any other cancer, making it resistant to chemotherapy. We evaluated the effect of Penfluridol against pancreatic cancer. Penfluridol treatment induced apoptosis and inhibited the growth of Panc-1, BxPC-3 and AsPC-1, pancreatic cancer cells with IC50 ranging between 6-7 muM after 24 h of treatment. Significant autophagy was induced by Penfluridol treatment in pancreatic cancer cells. Punctate LC3B and autophagosomes staining confirmed autophagy. Inhibiting autophagy by chloroquine, bafilomycin, 3-methyladenine or LC3BsiRNA, significantly blocked Penfluridol-induced apoptosis, suggesting that autophagy lead to apoptosis in our model. Penfluridol treatment suppressed the growth of BxPC-3 tumor xenografts by 48% as compared to 17% when treated in combination with chloroquine. Similarly, Penfluridol suppressed the growth of AsPC-1 tumors by 40% versus 16% when given in combination with chloroquine. TUNEL staining and caspase-3 cleavage revealed less apoptosis in the tumors from mice treated with Penfluridol and chloroquine as compared to Penfluridol alone. Penfluridol treatment also suppressed the growth of orthotopically implanted Panc-1 tumors by 80% by inducing autophagy-mediated apoptosis in the tumors. These studies established that Penfluridol inhibits pancreatic tumor growth by autophagy-mediated apoptosis. Since Penfluridol is already in clinic, positive findings from our study will accelerate its clinical development.
Penfluridol: An Antipsychotic Agent Suppresses Metastatic Tumor Growth in Triple-Negative Breast Cancer by Inhibiting Integrin Signaling Axis.[Pubmed:26627008]
Cancer Res. 2016 Feb 15;76(4):877-90.
Metastasis of breast cancer, especially to the brain, is the major cause of mortality. The inability of anticancer agents to cross the blood-brain-barrier represents a critical challenge for successful treatment. In the current study, we investigated the antimetastatic potential of Penfluridol, an antipsychotic drug frequently prescribed for schizophrenia with anticancer activity. We show that Penfluridol induced apoptosis and reduced the survival of several metastatic triple-negative breast cancer (TNBC) cell lines. In addition, Penfluridol treatment significantly reduced the expression of integrin alpha6, integrin beta4, Fak, paxillin, Rac1/2/3, and ROCK1 in vitro. We further evaluated the efficacy of Penfluridol in three different in vivo tumor models. We demonstrate that Penfluridol administration to an orthotopic model of breast cancer suppressed tumor growth by 49%. On the other hand, Penfluridol treatment inhibited the growth of metastatic brain tumors introduced by intracardiac or intracranial injection of breast cancer cells by 90% and 72%, respectively. Penfluridol-treated tumors from all three models exhibited reduced integrin beta4 and increased apoptosis. Moreover, chronic administration of Penfluridol failed to elicit significant toxic or behavioral side effects in mice. Taken together, our results indicate that Penfluridol effectively reduces the growth of primary TNBC tumors and especially metastatic growth in the brain by inhibiting integrin signaling, and prompt further preclinical investigation into repurposing Penfluridol for the treatment of metastatic TNBC.
